Verona Pharma (VRNA) News Today $51.89 -1.75 (-3.26%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Verona Pharma (NASDAQ:VRNA) Stock Price Down 3.1% - What's Next?Verona Pharma (NASDAQ:VRNA) Shares Down 3.1% - Here's WhyJanuary 17 at 2:16 PM | marketbeat.comVerona Pharma (NASDAQ:VRNA) Reaches New 1-Year High - Time to Buy?Verona Pharma (NASDAQ:VRNA) Sets New 1-Year High - Still a Buy?January 16 at 1:54 PM | marketbeat.comHennion & Walsh Asset Management Inc. Has $9 Million Stock Holdings in Verona Pharma plc (NASDAQ:VRNA)Hennion & Walsh Asset Management Inc. lifted its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 24.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 193,707 shares of the company's stock after acquiring an additional 37January 16 at 9:32 AM | marketbeat.comRecent High-Flyers: Top 10 Short-Term Picks That Skyrocketed!January 14, 2025 | markets.businessinsider.comVerona Pharma plc (NASDAQ:VRNA) Receives $50.57 Average PT from AnalystsJanuary 14, 2025 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Stock Price Up 4.5% - Should You Buy?Verona Pharma (NASDAQ:VRNA) Trading Up 4.5% - Still a Buy?January 13, 2025 | marketbeat.comRoth Capital Upgrades Verona Pharma (NASDAQ:VRNA) to "Strong-Buy"January 13, 2025 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Research Coverage Started at Roth MkmJanuary 13, 2025 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Upgraded to Strong-Buy at Roth CapitalRoth Capital upgraded Verona Pharma to a "strong-buy" rating in a report on Friday.January 11, 2025 | marketbeat.comRoth MKM Initiates Coverage of Verona Pharma plc - Depositary Receipt () (VRNA) with Buy RecommendationJanuary 11, 2025 | msn.comVerona Pharma plc (NASDAQ:VRNA) Given Consensus Recommendation of "Buy" by BrokeragesVerona Pharma plc (NASDAQ:VRNA - Get Free Report) has been assigned an average rating of "Buy" from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month price target amJanuary 11, 2025 | marketbeat.comAnalysts Expect Breakeven For Verona Pharma plc (NASDAQ:VRNA) Before LongJanuary 11, 2025 | finance.yahoo.comVerona Pharma (NASDAQ:VRNA) Now Covered by Roth MkmRoth Mkm began coverage on shares of Verona Pharma in a report on Friday. They issued a "buy" rating and a $68.00 price target for the company.January 10, 2025 | marketbeat.comTruist Financial Reaffirms "Buy" Rating for Verona Pharma (NASDAQ:VRNA)January 10, 2025 | americanbankingnews.comVerona Pharma price target raised to $77 from $51 at BTIGJanuary 9, 2025 | markets.businessinsider.comVerona Pharma Expects Strong Financial Performance for Q4 2024January 9, 2025 | americanbankingnews.comWells Fargo Sticks to Their Buy Rating for Verona Pharma (VRNA)January 8, 2025 | markets.businessinsider.comWells Fargo & Company Forecasts Strong Price Appreciation for Verona Pharma (NASDAQ:VRNA) StockWells Fargo & Company raised their price target on Verona Pharma from $64.00 to $74.00 and gave the company an "overweight" rating in a report on Wednesday.January 8, 2025 | marketbeat.comVerona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be LimitedJanuary 8, 2025 | seekingalpha.comVerona Pharma (NASDAQ:VRNA) Given Buy Rating at Truist FinancialTruist Financial reissued a "buy" rating and issued a $57.00 price objective (up from $44.00) on shares of Verona Pharma in a research note on Wednesday.January 8, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Reaches New 12-Month High - Still a Buy?Verona Pharma (NASDAQ:VRNA) Hits New 1-Year High - Here's What HappenedJanuary 8, 2025 | marketbeat.comVerona Pharma sees Q4 net product sales revenue $36M vs. $0M a year agoJanuary 7, 2025 | markets.businessinsider.comVerona Pharma (NASDAQ:VRNA) Shares Gap Up - Still a Buy?Verona Pharma (NASDAQ:VRNA) Shares Gap Up - Here's WhyJanuary 7, 2025 | marketbeat.comVerona posts early sales figures for Q4 and 2024January 7, 2025 | seekingalpha.comVerona Pharma Expects Preliminary Q4 Sales Of About $36 Mln From OhtuvayreJanuary 7, 2025 | markets.businessinsider.comVerona Pharma Reports Approximately $36 Million in Q4 2024 Net Sales for Ohtuvayre with Strong Prescription GrowthJanuary 7, 2025 | quiverquant.comTruist Financial Remains a Buy on Verona Pharma (VRNA)January 7, 2025 | markets.businessinsider.comVerona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial HighlightsJanuary 7, 2025 | markets.businessinsider.comVerona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial HighlightsJanuary 7, 2025 | globenewswire.comVerona Pharma (NASDAQ:VRNA) Trading Down 3.6% - Should You Sell?Verona Pharma (NASDAQ:VRNA) Shares Down 3.6% - Here's What HappenedJanuary 6, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Stock Price Down 2.5% - Here's WhyVerona Pharma (NASDAQ:VRNA) Stock Price Down 2.5% - Should You Sell?December 31, 2024 | marketbeat.comVerona Delivers 250% Return In Less Than A YearDecember 31, 2024 | markets.businessinsider.comVerona Pharma (NASDAQ:VRNA) Sets New 12-Month High - Here's What HappenedVerona Pharma (NASDAQ:VRNA) Sets New 52-Week High - Here's WhyDecember 30, 2024 | marketbeat.com16,458 Shares in Verona Pharma plc (NASDAQ:VRNA) Bought by Stifel Financial CorpStifel Financial Corp acquired a new position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,458 shares of the company'sDecember 28, 2024 | marketbeat.comTruist Financial Releases a Buy Rating on Verona Pharma (VRNA)December 23, 2024 | markets.businessinsider.comEuropean Equities Traded in the US as American Depositary Receipts Start Week Down Slightly in Monday TradingDecember 23, 2024 | msn.comFranklin Resources Inc. Takes $16.10 Million Position in Verona Pharma plc (NASDAQ:VRNA)Franklin Resources Inc. bought a new position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 559,728 shares of the company's stock, valued at approximatelDecember 21, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Given Consensus Rating of "Buy" by AnalystsVerona Pharma plc (NASDAQ:VRNA - Get Free Report) has been assigned a consensus rating of "Buy" from the six research firms that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1 year price target among analysts that hDecember 17, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Hits New 52-Week High - What's Next?Verona Pharma (NASDAQ:VRNA) Hits New 12-Month High - Here's WhyDecember 16, 2024 | marketbeat.comWellington Management Group LLP Buys 307,272 Shares of Verona Pharma plc (NASDAQ:VRNA)Wellington Management Group LLP raised its stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 19.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,878,632 shares of the company's stock after acquiring an additional 307,27December 12, 2024 | marketbeat.comVerition Fund Management LLC Acquires New Position in Verona Pharma plc (NASDAQ:VRNA)Verition Fund Management LLC bought a new position in Verona Pharma plc (NASDAQ:VRNA - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 17,170 shares of the company's stock, valued at approximately $494,000. OtherDecember 12, 2024 | marketbeat.comVerona Pharma (VRNA) Gets a Buy from Truist FinancialDecember 11, 2024 | markets.businessinsider.comFrazier Life Sciences Management L.P. Grows Stake in Verona Pharma plc (NASDAQ:VRNA)Frazier Life Sciences Management L.P. lifted its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 2.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,383,950 shares of the company's stock after purDecember 10, 2024 | marketbeat.comDorsey Wright & Associates Invests $2.31 Million in Verona Pharma plc (NASDAQ:VRNA)Dorsey Wright & Associates purchased a new stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 80,194 shares of the company's stock, valued aDecember 8, 2024 | marketbeat.comBNP Paribas Financial Markets Acquires 38,434 Shares of Verona Pharma plc (NASDAQ:VRNA)BNP Paribas Financial Markets raised its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 176.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 60,211 shares of the company's stock after buying an additional 38,434 shares duDecember 8, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Purchased by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company increased its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 77.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 105,159 shares of the company'sDecember 8, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Sells $290,920.00 in StockDecember 7, 2024 | insidertrades.comJanus Henderson Group PLC Sells 49,247 Shares of Verona Pharma plc (NASDAQ:VRNA)Janus Henderson Group PLC trimmed its holdings in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 4.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,042,795 shares of the company's stock afterDecember 7, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 58,184 SharesVerona Pharma plc (NASDAQ:VRNA - Get Free Report) CFO Mark W. Hahn sold 58,184 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $5.00, for a total value of $290,920.00. Following the completion of the transaction, the chief financial officer now directly owns 14,117,512 shares of the company's stock, valued at approximately $70,587,560. The trade was a 0.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.December 6, 2024 | marketbeat.comDavid Zaccardelli Sells 67,608 Shares of Verona Pharma plc (NASDAQ:VRNA) StockVerona Pharma plc (NASDAQ:VRNA - Get Free Report) CEO David Zaccardelli sold 67,608 shares of the company's stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $5.00, for a total value of $338,040.00. Following the transaction, the chief executive officer now directly owns 15,007,816 shares in the company, valued at approximately $75,039,080. The trade was a 0.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.December 6, 2024 | marketbeat.com Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address VRNA Media Mentions By Week VRNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRNA News Sentiment▼0.650.64▲Average Medical News Sentiment VRNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRNA Articles This Week▼124▲VRNA Articles Average Week Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GMAB News VTRS News ITCI News SMMT News MRNA News RDY News CTLT News SRPT News QGEN News PCVX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRNA) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRNA Stock Alerts